A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

被引：0
|
作者：
Anthony W. Tolcher
Leonard J. Appleman
Geoffrey I. Shapiro
Alain C. Mita
Frank Cihon
Arthur Mazzu
Pavur R. Sundaresan
机构：
[1] START (South Texas Accelerated Research Therapeutics),Early Drug Development Center, Department of Medical Oncology
[2] University of Pittsburgh Cancer Institute,Department of Medicine
[3] Dana-Farber Cancer Institute,Clinical Statistics
[4] Brigham and Women’s Hospital,Pharmacodynamics
[5] Harvard Medical School,undefined
[6] Institute for Drug Development,undefined
[7] Cancer Therapy and Research Center,undefined
[8] Bayer Healthcare Pharmaceuticals Inc.,undefined
[9] Bayer Healthcare Pharmaceuticals Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Cardiovascular adverse event (CAE); Left ventricular ejection fraction (LVEF); Hypertension; QT/QTc interval; Sorafenib; Cardiovascular profile;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：751 / 764
页数：13
相关论文
共 50 条
  • [31] HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
    Lin, Shi-Ming
    Lu, Sheng-Nan
    Chen, Ping-Tsung
    Jeng, Long-Bin
    Chen, Shinn-Cherng
    Hu, Chi-Tan
    Yang, Sien-Sing
    Le Berre, Marie-Aude
    Liu, Xuan
    Mitchell, David Y.
    Prins, Klaas
    Grevel, Joachim
    Pena, Carol A. E.
    Meinhardt, Gerold
    HEPATOLOGY INTERNATIONAL, 2017, 11 (02) : 199 - 208
  • [32] Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
    T Eisen
    R Marais
    A Affolter
    P Lorigan
    C Robert
    P Corrie
    C Ottensmeier
    C Chevreau
    D Chao
    P D Nathan
    T Jouary
    M Harries
    S Negrier
    E Montegriffo
    T Ahmad
    I Gibbens
    M G James
    U P Strauss
    S Prendergast
    M E Gore
    British Journal of Cancer, 2011, 105 : 353 - 359
  • [33] HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
    Shi-Ming Lin
    Sheng-Nan Lu
    Ping-Tsung Chen
    Long-Bin Jeng
    Shinn-Cherng Chen
    Chi-Tan Hu
    Sien-Sing Yang
    Marie-Aude Le Berre
    Xuan Liu
    David Y. Mitchell
    Klaas Prins
    Joachim Grevel
    Carol A. E. Peña
    Gerold Meinhardt
    Hepatology International, 2017, 11 : 199 - 208
  • [34] Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
    Huinink, Wim W. ten Bokkel
    Sufliarsky, Jozef
    Smit, Willem M.
    Spanik, Stanislav
    Wagnerova, Maria
    Hirte, Hal W.
    Kaye, Stan
    Johri, Anandhi R.
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3097 - 3103
  • [35] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    D. H. Palmer
    Y. T. Ma
    M. Peck-Radosavljevic
    P. Ross
    J. Graham
    L. Fartoux
    A. Deptala
    M. Studeny
    D. Schnell
    J. Hocke
    A-B. Loembé
    T. Meyer
    British Journal of Cancer, 2018, 118 : 1162 - 1168
  • [36] Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
    Faivre, Sandrine
    Raymond, Eric
    Boucher, Eveline
    Douillard, Jean
    Lim, Ho Y.
    Kim, Jun S.
    Zappa, Magaly
    Lanzalone, Silvana
    Lin, Xun
    DePrimo, Samuel
    Harmon, Charles
    Ruiz-Garcia, Ana
    Lechuga, Maria J.
    Cheng, Ann Lii
    LANCET ONCOLOGY, 2009, 10 (08): : 794 - 800
  • [37] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    Palmer, D. H.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Graham, J.
    Fartoux, L.
    Deptala, A.
    Studeny, M.
    Schnell, D.
    Hocke, J.
    Loembe, A-B.
    Meyer, T.
    BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1162 - 1168
  • [38] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    I. Kümler
    P. Grundtvig Sørensen
    J. Palshof
    E. Høgdall
    W. Skovrider-Ruminski
    S. Theile
    A. Fullerton
    P. G. Nielsen
    B. Vittrup Jensen
    D. L. Nielsen
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 169 - 178
  • [39] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    Kumler, I.
    Sorensen, P. Grundtvig
    Palshof, J.
    Hogdall, E.
    Skovrider-Ruminski, W.
    Theile, S.
    Fullerton, A.
    Nielsen, P. G.
    Jensen, B. Vittrup
    Nielsen, D. L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 169 - 178
  • [40] A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers
    Rubinstein, Maria M.
    Grisham, Rachel N.
    Cadoo, Karen
    Kyi, Chrisann
    Tew, William P.
    Friedman, Claire F.
    O'Cearbhaill, Roisin E.
    Zamarin, Dmitriy
    Zhou, Qin
    Iasonos, Alexia
    Nikolovski, Ines
    Xu, Hongmei
    Soldan, Krysten N.
    Caird, Imogen
    Martin, Madhuri
    Guillen, Joyce
    Eid, Khalil T.
    Aghajanian, Carol
    Makker, Vicky
    GYNECOLOGIC ONCOLOGY, 2021, 160 (01) : 71 - 76
12345